Evidence Hub

Dissemination of KPC-2-producing carbapenem-resistant Klebsiella pneumoniae ST656 in Eastern China

Chen Z, Yuan X, Han W, Shen L, Shi J, Yang J, Fu J, Yang C et al.

BMC microbiology, 2025

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly strains producing Klebsiella pneumoniae carbapenemase (KPC), pose a severe global health challenge due to limited therapeutic options and high mortality. While ST11 is the predominant KPC-producing lineage in China, the clinical and epidemiological significance of ST656 remains largely unexplored. We conducted a genomic and epidemiological investigation of twenty-five KPC-2-producing K. pneumoniae ST656 isolates collected from patients with severe pulmonary comorbidities in a tertiary hospital in Eastern China between July 2020 and October 2021. Antimicrobial susceptibility testing, whole-genome sequencing (WGS), phylogenetic analysis, plasmid profiling and conjugation assays were performed to determine resistance mechanisms, clonal relationships and plasmid transferability. Clinical information showed all 25 isolates originated from distinct patients in a tertiary hospital in Eastern China, predominantly older male post-lung transplantation cases with severe pulmonary disease, from intensive care units and thoracic surgery wards. All isolates displayed highly similar multidrug-resistant profiles, being resistant to most β-lactams, levofloxacin and trimethoprim-sulfamethoxazole, with limited susceptibility to amikacin and tigecycline. Genomic characterization of representative strain CRE132 showed that blaKPC−2 was located on a conjugative IncFII plasmid, and that this plasmid could transfer carbapenem…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free